Graham Capital Management L.P. Invests $498,000 in SI-BONE, Inc. (NASDAQ:SIBN)

Graham Capital Management L.P. purchased a new stake in SI-BONE, Inc. (NASDAQ:SIBN) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 35,487 shares of the company’s stock, valued at approximately $498,000. Graham Capital Management L.P. owned 0.08% of SI-BONE as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently bought and sold shares of SIBN. Mainstream Capital Management LLC bought a new position in SI-BONE in the fourth quarter worth approximately $53,000. R Squared Ltd bought a new position in shares of SI-BONE in the 4th quarter worth $73,000. KLP Kapitalforvaltning AS purchased a new stake in shares of SI-BONE during the 4th quarter worth $97,000. Proficio Capital Partners LLC bought a new stake in SI-BONE during the fourth quarter valued at about $155,000. Finally, AlphaQuest LLC raised its holdings in SI-BONE by 13,950.6% in the fourth quarter. AlphaQuest LLC now owns 11,662 shares of the company’s stock worth $164,000 after purchasing an additional 11,579 shares in the last quarter. Institutional investors own 98.11% of the company’s stock.

SI-BONE Price Performance

Shares of SIBN opened at $18.88 on Friday. The company has a debt-to-equity ratio of 0.22, a current ratio of 8.25 and a quick ratio of 7.22. The company’s fifty day moving average price is $14.74 and its 200-day moving average price is $14.97. The firm has a market capitalization of $804.57 million, a PE ratio of -20.52 and a beta of 0.82. SI-BONE, Inc. has a 1-year low of $11.70 and a 1-year high of $19.35.

SI-BONE (NASDAQ:SIBN) last issued its quarterly earnings results on Monday, May 5th. The company reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.24) by $0.09. SI-BONE had a negative net margin of 23.82% and a negative return on equity of 22.51%. The company had revenue of $47.29 million for the quarter, compared to the consensus estimate of $45.13 million. On average, equities research analysts predict that SI-BONE, Inc. will post -0.78 EPS for the current year.

Insiders Place Their Bets

In related news, CEO Laura Francis sold 38,504 shares of the firm’s stock in a transaction on Wednesday, May 7th. The shares were sold at an average price of $17.18, for a total transaction of $661,498.72. Following the sale, the chief executive officer now owns 302,958 shares in the company, valued at approximately $5,204,818.44. This trade represents a 11.28% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Anshul Maheshwari sold 4,937 shares of the company’s stock in a transaction dated Wednesday, May 7th. The stock was sold at an average price of $17.00, for a total transaction of $83,929.00. Following the completion of the transaction, the chief financial officer now owns 265,356 shares of the company’s stock, valued at approximately $4,511,052. This trade represents a 1.83% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 55,153 shares of company stock valued at $935,040. Company insiders own 4.00% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $25.00 price objective on shares of SI-BONE in a research report on Tuesday, May 6th. Needham & Company LLC reiterated a “buy” rating and set a $24.00 price objective on shares of SI-BONE in a report on Tuesday, May 6th. Finally, Truist Financial increased their price target on SI-BONE from $20.00 to $22.00 and gave the company a “buy” rating in a research note on Tuesday, May 6th.

SI-BONE Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.